CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
James M. Rae(University of Michigan), Mitch Dowsett(Institute of Cancer Research), Vered Stearns(Johns Hopkins University), Daniel F. Hayes(University of Michigan–Ann Arbor), Ivana Šestak(Cancer Research UK), S. Drury(Johns Hopkins University), Janine Salter(Nottingham City Hospital), Jacklyn N. Thibert(Johns Hopkins University), Ben P. Haynes(Institute of Cancer Research), Jack Cuzick(Queen Mary University of London)
Cited by 257
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k